


10-29-03

## EXPRESS MAIL CERTIFICATE

| | | |
|---|---|---|
| "Express Mail" mailing label number | : | EL 984 914 764 US |
| Date of Deposit | : | October 28, 2003 |
| Type of Documents | : | Information Disclosure Statement (2 pages);<br>Form PTO-1449 (5 pages) and References:<br>13 US Patents;<br>10 Foreign Patents;<br>78 Other Documents<br>Return Postcard |
| Serial No. | : | 10/607,930 |
| Filing Date: | : | June 27, 2003 |

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and are addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Diane H. Marshall (signature)
Diane H. Marshall

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

| | | | |
|---|---|---|---|
| Inventors: | Bhatti, *et al.* | Examiner: | To be assigned |
| Serial No.: | 10/607,930 | Art Unit: | 1614 |
| Filed: | June 27, 2003 | Docket No.: | T103 1530.1 |

For: **N-Aryl Diazaspiracyclic Compounds and Methods of Preparation and Use Thereof**

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants hereby voluntarily disclose the documents listed on the attached Form PTO-1449 to the Assistant Commissioner for Patents. This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits of the application. Accordingly, it is believed that no fees are due. However, should any fees be due, the Patent Office is hereby authorized to charge Deposit Account No. **09-0528**. A duplicate sheet is enclosed for this purpose.

Document F3 (EP 0 417 631 A2) is a copy of the published European Patent Application (German language only). Document D78, a bibliographic printout from DELPHION research service, containing an English language abstract apparently prepared by the DERWENT company. The abstract appears to suggest that the document comprises a discussion of condensed diazepinones of the general formula I (see published European patent application for formula I), having the substituents are recited therein. The document apparently alleges that such compounds are suitable for the therapy or cholinergically related spasms and motility disturbances in the gastrointestinal tract, in the billiary tract, for the symptomatic therapy of cystitis and of spasms associated with urolithiasis, for the therapy of relative incontinence, for the symptomatic therapy of bronchial asthma and of bronchitis, and for the therapy of ischaemic heart diseases.

The document D66 (Süess, Rudolf, "Regiospezifische Reduktionen von 1,3,3-trisubstituierten Succinimiden mit Diboran," *Helv. Chim. Acta* 60: 1650-1656 (1977)), in the German language, was published with an English abstract that appears to indicate that the document discusses the regiospecific reduction of 1,3,3-trisubstituted succinimides by diborane.

The document D67 (Sury, *et al.*, "Über Alkylenimin-Derivate. Beitrag zur Kenntnis der Diaza-spiro-undecane," *Helv. Chim. Acta* 36: 1815-1820 (1953)) in the German language, appears to indicate that the document discusses procedures for the preparation of diaza-spiro-undecanes.

Copies of one hundred one (101) documents are enclosed. Applicants further reserve the right to establish the patentability of the claimed invention over any of the listed information should they be applied as documents, and/or to prove that the cited information may not be prior art, and/or to prove that the cited information may not be enabling for the teachings they purport to offer. This statement further should not be construed as the representation that any search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of all available information, and to form independent opinions as to its significance.

It is respectfully requested that the Examiner initial and return copies of the enclosed PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

Respectfully submitted,

Date: Oct 27, 2003



Carl B. Massey, Jr.
Registration No. 44,224
Attorney for Applicants

**Docket: T103 1530.1**
Womble Carlyle Sandridge & Rice, PLLC
Post Office Box 7037
Atlanta, Georgia 30357-00378
Telephone (336) 721-3681
Facsimile(336) 726-8074

| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE | ATTY DKT NO.<br>T103 1530.1 | SERIAL NO.<br>10/607,930 |
|---|---|---|---|
| | | APPLICANT<br>Bhatti, *et al.* | |
| | **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** | FILING DATE<br>06-27-03 | GROUP<br>1614 |



**U.S. PATENT DOCUMENTS**

| EXAMINER INITIAL | | DOCUMENT NO. | DATE | NAME | CL. | SUBCL. | FILING DATE IF APPROP. |
|---|---|---|---|---|---|---|---|
| | P1 | 3,282,947 | 11/1966 | Grogan, *et al.* | 260 | 293 | |
| | P2 | 4,922,901 | 05/1990 | Brooks, *et al.* | 128 | 203.26 | |
| | P3 | 5,187,166 | 02/1993 | Kikuchi, *et al.* | 514 | 249 | |
| | P4 | 5,583,140 | 12/1996 | Bencherif, *et al.* | 514 | 299 | |
| | P5 | 5,597,919 | 01/1997 | Dull, *et al.* | 544 | 242 | |
| | P6 | 5,604,231 | 02/1997 | Smith, *et al.* | 514 | 256 | |
| | P7 | 5,616,716 | 04/1997 | Dull, *et al.* | 546 | 300 | |
| | P8 | 5,663,356 | 09/1997 | Ruecroft, *et al.* | 546 | 300 | |
| | P9 | 5,672,601 | 09/1997 | Cignarella | 514 | 249 | |
| | P10 | 5,733,912 | 03/1998 | Wasicak, *et al.* | 514 | 253 | |
| | P11 | 5,852,041 | 12/1998 | Cosford, *et al.* | 514 | 351 | |
| | P12 | 6,022,868 | 02/2000 | Olesen, *et al.* | 514 | 210 | |
| | P13 | US 2003/ 0092700 | 05/2003 | Czollner, *et al.* | 514 | 217.01 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

**FOREIGN PATENT DOCUMENTS**

| | | DOCUMENT NO. | DATE | COUNTRY | CL. | SUBCL | TRANSLATION | |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | YES | NO |
| | F1 | EP 0 297 858 | 01/1989 | EP | | | | |
| | F2 | EP 0 360 390 | 03/1990 | EP | | | | |
| | F3 | EP 0 417 631 | 03/1991 | EP | | | | |
| | F4 | GB 2 295 387 | 05/1996 | GB | | | | |
| | F5 | WO 94/08992 | 4/1994 | WO | | | | |
| | F6 | WO 96/31475 | 10/1996 | WO | | | | |
| | F7 | WO 96/40682 | 12/1996 | WO | | | | |
| | F8 | WO 97/40049 | 10/1997 | WO (See published English language related application P13 above) | | | | |
| | F9 | WO 98/25619 | 06/1998 | WO | | | | |
| | F10 | WO 99/21834 | 05/1999 | WO | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| EXAMINER | DATE CONSIDERED |
|---|---|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY DKT NO. T103 1530.1 | SERIAL NO. 10/607,930 |
|---|---|---|
| | APPLICANT Bhatti, *et al.* | |
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** | FILING DATE 06-27-03 | GROUP 1614 |



**OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)**

| | | |
|---|---|---|
| | D1 | Abramovitch, R.A., editor, "Pyridine and Its Derivatives," Supp. Part Three, pp. 3-5, in *Chemistry of Heterocyclic Compounds*, Volume 14 (Interscience Publishers, 1974). |
| | D2 | Adamcik, J.A., and E.J. Miklasiewicz, "Cyanoethylation. I. Weakly Basic Catalysts in the Reaction of Acrylonitrile with Active Methylene Compounds," *J. Org. Chem.* 28: 336-339 (1963). |
| | D3 | Arneric, S., *et al.*, "Preclinical Pharmacology of ABT-418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease," *CNS Drug Rev.*, 1(1): 1-26 (1995). |
| | D4 | Arneric, S.P., *et al.*, "Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease," *Exp. Opin. Invest. Drugs*, 5(1): 79-100 (1996). |
| | D5 | Bannon, A.W., *et al.*, "Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors," *Science*, 279: 77-81 (1998). |
| | D6 | Bencherif, M., *et al.*, "RJR-2403: A Nicotinic Agonist with CNS Selectivity I: *In Vitro* Characterization," *J. Pharmacol. Exper. Therapeutics*, 279(3): 1413-1421 (1996). |
| | D7 | Berkowitz, D.B., and M.K. Smith, "Enantiomerically Enriched α-Methyl Amino Acids. Use of an Acyclic, Chiral Alanine-Derived Dianion with a High Diastereofacial Bias," *J. Org. Chem.*, 60: 1233-1238 (1995). |
| | D8 | Brioni, J.D., *et al.*, "The Pharmacology of (–)-Nicotine and Novel Cholinergic Channel Modulators," *Adv. Pharmacol.*, 37: 153-215 (1997). |
| | D9 | Burger, A., *et al.*, "Some Derivatives of Tetrahydropyran as Potential Pharmacodynamic Agents," *J. Am. Chem. Soc.*, 72: 5512-5515 (1950). |
| | D10 | Cheng, Y., and W.H. Prusoff, "Relationship Between the Inhibition Constant ($K_I$) and the Concentration of Inhibitor which Causes 50 Per Cent inhibition ($I_{50}$) of an Enzymatic Reaction," *Biochem. Pharmacol.* 22(23): 3099-3108 (1973). |
| | D11 | Chiari, A., *et al.*, "Sex Differences in Cholinergic Analgesia I: A Supplemental Nicotinic Mechanism in Normal Females," *Anesthesiology*, 91(5): 1447-1454 (1999). |
| | D12 | Ciblat, S., *et al.*, "A new route to 2-spiropiperidines," *Tet. Lett.*, 42: 4815-4817 (2001). |
| | D13 | Clarke, K., and K. Rothwell, "A Kinetic Study of the Effect of Substituents on the Rate of Formation of Alkylpyridinium Halides in Nitromethane Solution,"*J. Chem. Soc.*, 1885-1895 (1960). |
| | D14 | Comins, D.L, and M.O. Killpack, "Lithiation of Methoxypyridines Directed by α-Amino Alkoxides," *J. Org. Chem.*, 55(1): 69-73 (1990). |
| | D15 | Cosford, N.D.P., *et al.*, "(S)-(—) 5- Ethynyl-3-(1-methyl-2-pyrrolidinyl) pyridine Maleate (SIB-1508Y): A Novel Anti-Parkinsonian Agent with Selectivity for Neuronal Nicotinic Acetylcholine Receptors," *J. Med. Chem.*, 39(17) : 3235-3237 (1996). |
| | D16 | Culbertson, T.P., *et al.*, "Quinolone Antibacterial Agents Substituted at the 7-Position with Spiroamines. Synthesis and Structure-Activity Relationships," *J. Med. Chem.*, 33(8): 2270-2275 (1990). |
| | D17 | Damaj, M.I., *et al.*, "Analgesic Activity of Metanicotine, A Selective Nicotinic Agonist," *Society for Neuroscience*, 23: 669 ABSTRACT 266.9 (1997). |
| | D18 | Damaj, M.I., *et al.*, "Antinociceptive and Pharmacological Effects of Metanicotine, a Selective Nicotinic Agonist," *J. Pharmacol. Exp. Ther.*, 291(1): 390-398 (1999). |
| | D19 | Decina, P., *et al.*, "Cigarette Smoking and Neuroleptic-Induced Parkinsonism," *Biol. Psychiatry*, 28(6): 502-508 (1990). |
| | D20 | Elliott, J.M., *et al.*, "Serine Derived $NK_1$ Antagonists 2: A Pharmacophore Model for Arylsulfonamide Binding," *Bioorg. Med. Chem. Lett.*, 8: 1851-1856 (1998). |
| | D21 | Fornicola, R.S., *et al.*, "A New Synthesis of α-Amino Acid Derivatives Employing Methyl Nitroacetate as a Versatile Glycine Template," *J. Org. Chem.*, 63(11): 3528-3529 (1998). |
| | D22 | Genin, M.J., *et al.*, "Synthesis and Crystal Structure of a Peptidomimetic Containing the (*R*)-4.4-Spiro Lactam Type-II β-Turn Mimic," *J. Org. Chem.*, 58(8): 2334-2237 (1993). |
| | D23 | Genin, M.J., and R.L. Johnson, "Design, Synthesis, and Conformational Analysis of a Novel Spiro-Bicyclic System as a Type II β-Turn Peptidomimetic," *J. Amer. Chem. Soc.*, 114(23): 8778-8783 (1992). |

| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY DKT NO. T103 1530.1 | SERIAL NO. 10/607,930 |
|---|---|---|
| | APPLICANT Bhatti, *et al.* | |
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** | FILING DATE 06-27-03 | GROUP 1614 |



| | | |
|---|---|---|
| | D24 | Gibson, S., *et al.*, "Principal Components Describing Biological Activities and Molecular Diversity of Heterocyclic Aromatic Ring Fragments," *J. Med. Chem.*, 39(20): 4065-4072 (1996). |
| | D25 | Grogan, C.H., *et al.* "Spiranes. VII. Neuroleptics Derived from Azaspiranes," *J. Med. Chem.*, 8: 62-73 (1965). |
| | D26 | Hall, G.H., and D.M. Turner, "Effects of Nicotine on the Release of $^3$H-Noradrenaline from the Hypothalamus," *Biochemical Pharmacology*, 21: 1829-1838 (1972). |
| | D27 | Hamon, M., "Neuropharmacology of anxiety: perspectives and prospects," *TiPS*, 15: 36-39 (1994). |
| | D28 | Hansch, C., *et al.*, "The Parabolic Dependence of Drug Action upon Lipophilic Character as Revealed by a Study of Hypnotics," *J. Med. Chem.*, 11(1): 1-11 (1967). |
| | D29 | Hansch, C., *et al.*, "A Survey of Hammett Substituent Constants and Resonance and Field Parameters," *Chem. Rev.*, 91(2): 165-195 (1991). |
| | D30 | Hansen, M.M., *et al.*, "An Enantioselective Synthesis of Cis Perhydroisoquinoline LY235959," *J. Org. Chem.*, 63(3): 775-785 (1998). |
| | D31 | Harsing, Jr., L.G., *et al.*, "Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization," *J. Neurochem.*, 59(1): 48-54 (1992). |
| | D32 | Hartwig, J.F., *et al.*, "Room-Temperature Palladium-Catalyzed Amination of Aryl Bromides and Chlorides and Extended Scope of Aromatic C—N Bond Formation with a Commerical Ligand," *J. Org. Chem.*, 64(15): 5575-5580 (1999). |
| | D33 | Hertog, H.J.D., *et al.*, "The Directive Influence of the N-Oxide Group During the Nitration of Derivatives of Pyridine N-Oxide (IV) [1]) Nitration of 3-bromo-5methoxy- and 3,5-dimethoxy-pyridine-N-oxide[2]," *Recueil Trav. Chim. Pays-Bas*, 74(8/9): 1171-1179 (1955). |
| | D34 | Hery, F., *et al.*, "Control of the Release of Newly Synthetized $^3$H-5-Hydroxytryptamine by Nicotinic and Muscarinic Receptors in Rat Hypothalamic Slices," *Naunyn-Schmiedeberg's Arch. Pharmacol.*, 296: 91-97 (1977). |
| | D35 | Hinds, M.G., *et al.*, "Synthesis, Conformational Properties, and Antibody Recoginition of Peptides Containing β-Turn Mimetics Based on α-Alkylproline Derivatives," *J. Med. Chem.*, 34(6): 1777-1789 (1991). |
| | D36 | Hoffman, J.M., *et al.*, "Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1-Specific Reverse Transcriptase Inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one and Analogues," *J. Med. Chem.*, 36(8): 953-966 (1993). |
| | D37 | Holladay, M.W., *et al.*, "Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery," *J. Med. Chem*, 40(26): 4169-4194 (1997). |
| | D38 | Holland, A. *et al.*, "Isothiazoles. Part IX. Isothiazolopyrimidines," *J. Chem. Soc.*, 7277-7282 (1965). |
| | D39 | Hughes, D.L., "The Mitsunobu Reaction," *Org. React.*, 42: 335-657 (1992). |
| | D40 | Hughes, D.L., "Progress in the Mitsunobu Reaction. A Review," *Org. Prep. Proced. Int.*, 28(1): 129-164 (1996). |
| | D41 | Islam, A.M., and R.A. Raphael, "A Direct Transformation of cycloHexanones into bicyclo [5: 3: 0] *Dec-7-en-9-ones*," *J. Chem. Soc.*, 3151-3154 (1955). |
| | D42 | Kim, K., *et al.*, "Novel Bicyclic Lactams as XaaPro Type VI β Turn Mimics: Design, Synthesis and Evaluation," *J. Org. Chem.*, 61(9): 3138-3144 (1996). |
| | D43 | Lall, M.S., *et al.*, "Serine and Threonine β-Lactones: A New Class of Hepatitis A Virus 3C Cysteine Proteinase Inhibitors," *J. Org. Chem.*, 67(5): 1536-1547 (2002). |
| | D44 | Latli, B., *et al.*, "Novel and Potent 6-Chloro-3-pyridinyl Ligands for the α4β2 Neuronal Nicotnic Acetylcholine Receptor," *J. Med. Chem.*, 42(12): 2227-2234 (1999). |
| | D45 | Lavand'homme, P., and J.C. Eisenach, "Sex Differences in Cholinergic Analgesia II: Differing Mechanisms in Two Models of Allodynia," *Anesthesiology*, 91(5): 1455-1461 (1999). |
| | D46 | Lippiello, P.M., *et al.*, "RJR-2403: A Nicotinic Agonist with CNS Selectivity II. *In Vivo* Characterization," *J. P. E. T.*, 279(3): 1422-1429 (1996). |
| | D47 | Majer, Z., *et al.*, "Synthesis and Absolute Configuration of 1,7 Diazaspiro[4,4]Nonane-2,6-Dione," *Coll. Czech. Chem. Comm.*, 47(3): 950-960 (1982). |
| | D48 | Old, D.W., *et al.*, "A Highly Active Catalyst for Palladium-Catalyzed Cross-Coupling Reactions: Room-Temperature Suzuki Couplings and Amination of Unactivated Aryl Chlorides," *J. Am. Chem. Soc.*, 120(37): 9722-9723 (1998). |

(Form PTO-1449)

| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY DKT NO. T103 1530.1 | SERIAL NO. 10/607,930 |
|---|---|---|
| | APPLICANT Bhatti, *et al.* | |
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** | FILING DATE 06-27-03 | GROUP 1614 |



| | | |
|---|---|---|
| | D49 | Onaivi, E.S., *et al.*, "Chronic Nicotine Reverses Age-Associated Increases in Tail-Flick Latency and Anxiety in Rats," *Life Sciences*, 54(3): 193-202 (1994). |
| | D50 | Overberger, *et al.*, "Absolute Configuration of 2,7 Diazaspiro[4.4]nonane. A Reassignment," *J. Org. Chem.*, 46(13): 2757-2764 (1981) |
| | D51 | Overman, L.E., and R.M. Burk, "A Convenient Synthesis of Unsymmetrical Secondary Amines. In Situ Formation of Unstable Formaldehyde Imines," *Tet. Lett.*, 25(16): 1635- 1638 (1984). |
| | D52 | Pedersen, M.L., and D.B. Berkowitz, "Formal α-Vinylation of Amino Acids. Use of a New Benzeneselenolate Equivalent," *J. Org. Chem.*, 58(25): 6966-6975 (1993). |
| | D53 | Pomerleau, O.F., *et al.*, "The Effects of Cigarette Smoking on Pain and Anxiety," *Addictive Behaviors*, 9: 265-271 (1984). |
| | D54 | Pullan, R.D., *et al.* "Transdermal Nicotine for Active Ulcerative Colitis," *New England J. Med.*, 330(12): 811-815 (1994). |
| | D55 | Radziszewski, J.G., *et al.*, "Twisted Si=N Bonds: Matrix Isolation of Bridgehead Silanimines," *J. Am. Chem. Soc.*, 115(18): 8401-8408 (1993). |
| | D56 | Ranganathan, D., *et al.*, "Nitroethylene: A Stable, Clean, and Reactive Agent for Organic Synthesis," *J. Org. Chem.*, 45(7): 1185-1189 (1980). |
| | D57 | Rapier, C., *et al.*, "Stereoselective Nicotine-Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation," *J. Neurochem.*, 50(4): 1123-1130 (1988). |
| | D58 | Reiter, L.A., "Synthesis of 4(5)-Acyl-, 1-Substituted 5-Acyl-, and 1-Substituted 4-Acyl-1H-iimidazoles from 4-Aminosioxazoles," *J. Org. Chem.*, 52(13): 2714-2726 (1987). |
| | D59 | Ricciardi, F.J., and P.H. Doukas, "Facile Synthesis of Styrlquinuclidines," *Heterocycles*, 24(4): 971-977 (1986). |
| | D60 | Rice, L.M., *et al.*, "Spiranes. V(1) A Synthetic Route to Symmetrical and Unsymmetrical 3,9-Diazaspiro [5.5] undecanes," *J. Het. Chem.*, 1(3): 125-127 (1964). |
| | D61 | Rowell, P.P. and D.L. Winkler, "Nicotinic Stimulation of [$^3$ H] Acetylcholine Release from Mouse Cerebral Cortical Synaptosomes," *J. Neurochem.*, 43(6): 1593-1598 (1984). |
| | D62 | Sanberg, P.R., *et al.*, "Nicotine Potentiation of Haloperidol-Induced Catalepsy: Striatal Mechanisms," *Pharmacol. Biochem. & Behavior*, 46: 303-307 (1993). |
| | D63 | Sandor, N.T., *et al.* "Effect of nicotine on dopaminergic-cholinergic interaction in the striatum," *Brain Res.*, 567: 313-316 (1991). |
| | D64 | Selnick, H.G., *et al.*, "Preparation and Trapping of 3-Lithium-O-Lithiophenoxide," *Tet. Lett.*, 34(13): 2043-2046 (1993). |
| | D65 | Smith, P.W., *et al.*, "New Spiropiperidines as Potent and Selective Non-Peptide Tachykinin $NK_2$ *Receptor Antagonists," J. Med. Chem.*, 38(19): 3772-3779 (1995). |
| | D66 | Süess, R. and A.G. Sandoz, "Regiospezifische Reduktionen von 1,3,3-trisubstituierten Succinimiden mit Diboran," *Helv. Chim. Acta*, 60: 1650-1656 (1977). |
| | D67 | Sury, E., and K. Hoffmann, "Über Alkylenimin-Derivate. Beitrag zur Kenntnis der Diaza-spiro-undecane," *Helv. Chim. Acta*, 36: 1815-1820 (1953). |
| | D68 | Thomas, J. and D. Clough, "The Preparation and Measurement of the Surface Activity of a Series of 4-Alkyl-1,1′-Spirobipiperidinium Bromides," *J. Pharm. Pharmacol.*, 15(3): 167-177 (1963). |
| | D69 | Toth, E., *et al.*, "Effect of Nicotine of Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions: Role of Glutamic Acid," *Neurochem. Res.*, 17(3): 265-270 (1992). |
| | D70 | Tripathi, H.L., *et al.*, "Nicotine-Induced Antinociception of Rats and Mice: Correlation with Nicotine Brain Levels," *J. Pharmacol. Exp. Ther.*, 221(1): 91-96 (1982). |
| | D71 | Vizi, E.S., "Acetylcholine release from guinea-pig ileum by parasympathetic ganglion stimulants and gastrin-like polypeptides," *Br. J. Pharmac.*, 47: 765-777 (1973). |
| | D72 | Wagaw, S. and S.L. Buchwald, "The Synthesis of Aminopyridines: A Method Employing Palladium-Catalyzed Carbon-Nitrogen Bond Formation," *J. Org. Chem.*, 61(21): 7240-7241 (1996). |
| | D73 | Wagner, B., *et al.*, "Does Smoking Reduce the Risk of Neuroleptic Parkinsonoids?," *Pharmacopsychiat.*, 21: 302-303 (1988). |

| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY DKT NO. T103 1530.1 | SERIAL NO. 10/607,930 |
|---|---|---|
| | APPLICANT Bhatti, *et al.* | |
| **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** | FILING DATE 06-27-03 | GROUP 1614 |



| | | |
|---|---|---|
| | D74 | Wittekind, R.R., and C. Weissman, "Synthesis of the 1,8-Diazaspiro [4.5] decane System," *J. Het. Chem.*, 9(1): 111-113 (1972). |
| | D75 | Williams, M., *et al.*, "Neuronal Nicotinic Acetylcholine Receptors," *Drug News Perspec.*, 7(4): 205-223 (1994). |
| | D76 | Zhu, J., *et al.* "Asymmetric Synthesis. 29.[1] Preparation of 1,8-Diazaspiro{5.5] undecane Derivatives," *J. Org. Chem.*, 58(23): 6451-6456 (1993). |
| | D77 | Zwart, C., and J.P. Wibaut, "Chemical Behaviour of 3-Aminopyridine and of 3,5-Diaminopyridine. Syntheses of (3-Pyridyl)-Pyrazolones." *Recueil Trav. Chim. Pays-Bas*, 74(8/9): 1062-1069 (1955). |
| | D78 | Delphion Printout – Bibliographic Data for EP 0417 631 A2 (Document F3) shows Derwent English language abstract. Oct. 21, 2003. |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| EXAMINER | DATE CONSIDERED |
|---|---|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.